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Abstract
Introduction: Rheumatoid arthritis (RA) frequently involves the loss of tolerance to citrullinated antigens, which
may play a role in pathogenicity. Citrullinated fibrinogen is commonly found in inflamed synovial tissue and is a
frequent target of autoantibodies in RA patients. To obtain insight into the B-cell response to citrullinated
fibrinogen in RA, its autoepitopes were systematically mapped using a new methodology.
Methods: Human fibrinogen was citrullinated in vitro by peptidylarginine deiminases (PAD), subjected to
proteolysis and the resulting peptides were fractionated by ion exchange chromatography. The peptide
composition of the citrullinated peptide-containing fractions was determined by high resolution tandem mass
spectrometry. The recognition of these fractions by patient sera was subsequently analyzed by imaging surface
plasmon resonance on microarrays.
Results: In total about two-thirds of the 81 arginines of human fibrinogen were found to be susceptible to
citrullination by the human PAD2, the human PAD4 or the rabbit PAD2 enzymes. Citrullination sites were found in
all three polypeptide chains of fibrinogen, although the a-chain appeared to contain most of them. The analysis of
98 anti-citrullinated protein antibody-positive RA sera using the new methodology allowed the identification of
three major citrullinated epitope regions in human fibrinogen, two in the a- and one in the b-chain.
Conclusions: A comprehensive overview of citrullination sites in human fibrinogen was generated. The multiplex
analysis of peptide fractions derived from a post-translationally modified protein, characterized by mass
spectrometry, with patient sera provides a versatile system for mapping modified amino acid-containing epitopes.
The citrullinated epitopes of human fibrinogen most efficiently recognized by RA autoantibodies are confined to
three regions of its polypeptides.
Introduction
Rheumatoid arthritis (RA) is a common autoimmune dis-
ease, in which several autoantigens have been identified,
including fibrinogen [1-3]. Fibrinogen consists of two
copies of each of its three polypeptide chains a, b and
g [4]. Fibrinogen is involved in the clotting cascade, in
which it is converted into fibrin, a process mediated by
thrombin [5]. Autoantibodies against citrullinated proteins
(ACPA) have been shown to be specifically associated with
RA and are already present prior to disease onset [6].
Citrullination, the conversion of peptidylarginine into pep-
tidylcitrulline, of the fibrinogen a and b chains generates
antigenic targets for autoantibodies present in the serum
and synovial fluid of RA patients [1,7].
For the diagnosis of RA, besides the clinical symptoms,
tests for detecting autoantibodies, such as rheumatoid
factor (RF test) or ACPA (which are generally detected
with the so-called cyclic citrullinated peptide, CCP, test)
can be useful [8]. Autoantibodies to citrullinated human
f i b r i n o g e nm a yh a v eg r e a tvalue for the diagnosis of
RA [9]. Vander Cruyssen and colleagues compared an
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test and detected similar diagnostic performance [10].
The role of citrullinated proteins and ACPA in the
pathophysiology of RA is not fully understood, but it has
been shown that citrullinated fibrinogen can induce
arthritis in genetically susceptible (DR4-IE transgenic)
mice [7]. Recently, Ho and others found that mice that
were immunized with citrullinated fibrinogen developed
arthritis and fibrinogen-reactive T cells which produce
the proinflammatory cytokines IL-6, IL-17, TNF-a,a n d
IFN-g and that these mice possess rheumatoid factor, cir-
culating immune complexes and anti-CCP, all of which
are characteristics of human RA [11]. In vitro studies by
Clavel and co-workers showed that immune-complexes
consisting of ACPA and citrullinated fibrinogen can
induce macrophage secretion of TNF-a, which is an
important mediator of inflammation [12]. In humans, an
association was detected between the occurrence of the
R As u s c e p t i b l eH L A - D R B 1a l l e l ea n dt h ep r e s e n c eo f
anti-citrullinated fibrinogen antibodies [13]. Finally, cir-
culating immune complexes containing citrullinated
fibrinogen were found in a large subset of ACPA-positive
RA patients [14]. These findings suggest a crucial role for
fibrinogen in RA pathogenesis. Several studies have
addressed the position of citrullinated autoepitopes in
human fibrinogen [4,7,9,15,16]. Most of these studies
were performed with synthetic citrullinated fibrinogen
peptides in combination with ELISA detection. Here, we
describe a novel method to map the epitopes of post-
translationally modified proteins and apply this method,
which is schematically illustrated in Figure 1, to map
the autoepitopes of citrullinated fibrinogen recognized by
RA sera.
Materials and methods
In vitro citrullination of fibrinogen
To generate deiminated fibrinogen, 1 mg of immunoglo-
bulin-depleted human fibrinogen (Sigma-Aldrich, St.
Louis, Missouri, USA) was in vitro citrullinated by either
human PAD2 (hPAD2; 1 U), human PAD4 (hPAD4;
1 U) or rabbit muscle PAD (rmPAD2; 1 U; Sigma-
Aldrich) in deimination buffer (40 mM Tris-HCl, pH
7.5, 5 mM CaCl2 a n d1 0m MD T T )a n di n c u b a t e da t
37°C for three hours. After incubation, the reaction mix-
tures were dialyzed against phosphate-buffered saline
overnight.
The recombinant hPAD2 and hPAD4 were expressed
and purified as described previously [17]. The activity of
both recombinant proteins was determined with a col-
orimetric assay [18,19].
Western blot analysis
Human fibrinogen was separated by SDS-PAGE and
transferred to nitrocellulose membranes. For the
detection of citrullinated proteins, blots were chemically
modified overnight as described previously [20]. After
blocking the blots in blocking buffer (5% non-fat dried
milk and 0.1% NP40 in PBS) for one hour at room tem-
perature, they were incubated with the anti-modified
citrulline antibody (Upstate, Billerica, Massachusetts,
USA) in blocking buffer for three hours at room tem-
perature. Finally, the blots were washed with blocking
Figure 1 Autoepitope mapping of citrullinated fibrinogen.
Schematic overview of the novel method used to characterize the
citrullinated epitopes on human fibrinogen recognized by RA
patient autoantibodies.
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IRDye 800-labeled seconda r ya n t i b o d y( M o l e c u l a r
Probes, Rockland Immunochemicals, Gilbertsville, Penn-
sylvania, USA) and monitored by infrared (LI-COR
Odyssey, Lincoln, Nebraska, USA) imaging.
Enzymatic digestion of citrullinated fibrinogen
Different proteases were used for the generation of
citrullinated fibrinogen peptides to achieve optimal
sequence coverage in mass spectrometry analyses and to
obtain citrullinated epitopes in different sequence con-
texts for surface plasmon resonance imaging analyses.
Citrullinated fibrinogen was reduced using 50 mM
DTT, alkylated in 100 mM iodoacetamide and digested
with trypsin (all PADs), chymotrypsin (all PADs), Lys-N
(rmPAD2 only), or GluC (hPAD2 and hPAD4), in a
1:100 ratio by overnight incubation at 37°C.
Separation of fibrinogen peptide fragments
Peptides obtained by digestion of fibrinogen citrullinated
by rmPAD2 were separated using strong cation
exchange (SCX) chromatography, which was performed
using an Agilent 1100 HPLC system (Agilent Technolo-
gies, Santa Clara, California, USA) with two C18 Opti-
Lynx (Optimized Technologies, Oregon City, Oregon,
USA) guard columns and a polysulfoethyl A SCX col-
u m n( P o l y L C ,C o l u m b i a ,M D ,U S A ;2 0 0m m×2 . 1m m
inner diameter, 5 μm, 200Å), essentially as described
previously [21]. Ten percent of each fraction was ana-
lyzed by LC-MS/MS. Fractions containing a large over-
lap in citrullinated peptides were pooled prior to SPR
analysis. This led to a total of 29 fractions, derived from
either the chymotrypsin (C), Lys-N (L) or trypsin (T)
digestion. Each selected fraction was desalted and dried
prior to immobilization on the sensor disc surface.
LC-MS/MS
Digested citrullinated fibrinogen samples were analyzed
by nano-LC-MS/MS on an LTQ-Orbitrap-XL using elec-
tron transfer induced dissociation (ETD) (hPAD2
a n dh P A D 4 )a n d / o ra nL T Q - F T I C R( a l lP A D s )m a s s
spectrometer using collision induced dissociation (CID)
(Thermo, San Jose, CA, USA) connected to an Agilent
1200 series nano-LC system. Peptides were separated on
C18 with a multi-step gradient of 0.6% acetic acid (buffer
A) and 0.6% acetic acid/80% acetonitrile (buffer B). Raw
MS data were converted to peak lists using Bioworks
Browser software, version 3.1.1 (Thermon Finnigan, San
Jose, California, USA) and searched with Mascot against
the Swiss-Prot database (Swiss Institute of Bioinfor-
matics, Lausanne, Switzerland), using the appropriate
enzyme and allowing citrullination of arginine, deamida-
tion of asparagine and oxidation of methionine as vari-
able modifications. The spectra from the hPAD2 and
hPAD4 fibrinogen incubations were searched with a
precursor mass tolerance of 20 ppm and a product mass
tolerance of 0.9 Da, allowing two miscleavages, with pep-
tide identifications accepted with a Mascot score greater
than 25. For the SCX separated rmPAD2 modified
peptides, precursor tolerance was 5 ppm, product mass
tolerance 0.9 Da, allowing one miscleavage and peptide
identifications were accepted with a slightly lower Mascot
s c o r eo fa tl e a s t2 0t ob ea b l et ob e t t e ri d e n t i f yo v e r l a p
between adjacent fractions.
Preparation of the microarrays and iSPR analyses
To prepare the fibrinogen peptides for immoblization on
the surface plasmon resonance (SPR) sensor discs, it was
chosen not to use the GluC protease, which is known
for its incomplete and heterogeneous cleavage, making
it not very suitable for this application. Instead, Lys-N
was used, which cleaves at the N-terminal side of lysine
residues, thereby generating peptides that would always
be immobilized in the same orientation, because both
primary amines available for crosslinking are located at
the N-terminus of the peptide. In addition to LysN,
trypsin and chymotrypsin were used to digest human
fibrinogen citrullinated in vitro with rmPAD2. The latter
PAD was used for these experiments, because its specific
activity is higher than that of the recombinant human
PADs, implying that lower quantities could be used,
which reduces the presence of PAD-derived peptides in
the citrullinated fibrinogen fractions.
Fibrinogen peptide fractions were immobilized on an
iSPR chip containing a dextran hydrogel linked to a
gold layer on a round glass surface (HC200, Xantec
Bioanalytics GmbH, Dusseldorf, Germany). In short,
immobilization of the fibrinogen peptide fractions was
initiated by activation of the dextran hydrogel, which is
achieved by creating a reactive N-hydroxysuccinimide
ester with the carboxyl groups of the dextran matrix via
the reaction which occurs when 0.8 M N-hydroxysucci-
nimide (NHS) and 0.2 M N-ethyl-N’-(dimethylamino-
propyl) carbodiimide hydrochloride (EDC) are mixed
and added to the sensor disc surface. After incubation
for 20 minutes the sensor disc was washed with 0.25%
acetic acid, pH 4.5 and dried under nitrogen for 30 min-
utes. The protease-digested, citrullinated fibrinogen SCX
fractions, human IgG (to visualize the array) and control
synthetic peptides (citrullinated peptides and their argi-
nine-containing counterparts) were spotted on the
surface of the sensor discs using a noncontact spotter
(1 nl droplets with spotting concentration of 1 ng/nl in
50 mM MES, pH 5.4) and placed in a humidity chamber
at room temperature for 1 h. Finally, the unreacted
groups were blocked by incubation with 1 M ethanola-
m i n e ,p H8 . 0f o r1 0m i n u t e s .T h es e n s o rd i s c sw e r e
rinsed with PBS and kept wet until use.
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regeneration of the coated sensor discs were performed
as described previously [22,23]. In contrast to previous
studies, a new valveless sample injection method
in combination with high mass transport of analytes
was used.
Multiplex iSPR analyses of fibrinogen peptide recognition
by patient sera
Sera from rheumatoid arthritis patients were obtained
from the Department of Rheumatology, University Med-
ical Center St. Radboud, Nijmegen, The Netherlands.
The use of autoimmune patient sera for autoantibody
studies has institutional review board approval and
patients provided informed consent. Prior to use, sera
were 50-fold diluted in PBS-0.03% Tween-20. Using the
IBIS-iSPR instrument a diluted serum sample plug of
80 μl was injected and 20 μl was guided backward and
forward over the microarray of fibrinogen peptide frac-
tions in a flow cell with a speed of 30 μl/s to allow auto-
antibody binding to the immobilized peptides.
To obtain quantitative results for antibody binding to
the peptide fractions, the data were analyzed by the
SPRint software (IBIS Technologies BV., Enschede, The
Netherlands). Spots were classified as being strongly or
moderately recognized by sera when at least 25% of the
sera were reactive with these fractions with angle shifts
higher than the mean plus eight, respectively two, stan-
dard deviations of the angle shift observed for a number
of anti-CCP-negative RA sera.
Results
Identification of citrullination sites in human fibrinogen
To generate a map of the citrullinated autoantigenic epi-
topes on human fibrinogen, the protein was first citrulli-
nated in vitro using recombinant hPAD2 and hPAD4, as
well as rabbit muscle PAD (rmPAD2). To check the
resulting citrullination of the protein, the reaction pro-
ducts were analyzed by SDS-PAGE and Coomassie brilli-
ant blue staining. Bands corresponding to the a-, b-a n d
g-chains of fibrinogen were detected and upon incubation
with PAD the migration of the a-chain and, although to a
much lesser extent, that of the b-chain were changed
(Figure 2a). To confirm that this migration shift was due
to citrullination, blots containing the same samples were
analyzed using the anti-modified citrulline antibody pro-
cedure (Figure 2b). The results showed that all fibrinogen
chains were citrullinated by all PADs, although citrullina-
tion by hPAD4 appeared to be less efficient than that of
the other PADs. In agreement with its migration shift,
the a-chain displayed the highest levels of citrullination
upon incubation with hPAD2 and rmPAD2. To exclude
that the lower levels of fibrinogen citrullination by
hPAD4 was due to differences in the specific activity of
t h eP A De n z y m e s ,t h es a m ea m o u n to ff i b r i n o g e n
was incubated with increasing amounts of hPAD4 (up to
20 U/mg substrate). However, this did not lead to
increased levels of citrullination (data not shown), sug-
gesting that hPAD4 is more restrictive in citrullination of
fibrinogen than hPAD2 and rmPAD2.
To obtain a comprehensive overview of the residues in
human fibrinogen that are citrullinated by hPAD2 and
hPAD4, citrullinated fibrinogen was proteolytically
digested with three different enzymes (trypsin, chymo-
trypsin, GluC), to optimize the sequence coverage and
to eliminate the influence of citrullination on cleavage.
All digests were analyzed by LC-MS/MS using both CID
and ETD fragmentation to obtain as much sequence
information as possible. This allowed the identification
of 42 citrullinated residues, 27 of which were found in
the a-chain, 11 in the b-chain and 4 in the g-chain of
human fibrinogen (Figure 3). The total coverage of the
mature fibrinogen polypeptide sequences obtained by
this approach was similar in all experiments, approxi-
mately 91% for the a-chain, 86% for the b-chain and
89% for the g-chain. The majority of the citrullination
sites were identified in fibrinogen treated with hPAD2.
In the a-chain, 27 arginines were deiminated by hPAD2,
17 of which were also citrullinated by hPAD4. No argi-
nines that were specifically deiminated by hPAD4 were
detected. In the b-chain, six arginine residues were dei-
minated by both hPAD2 and hPAD4, three only by
hPAD2 and two only by hPAD4. Finally, in the g-chain
four citrullination sites were identified, three for each of
t h et w oP A D s ,t w oo fw h i c hw e r ec i t r u l l i n a t e db yb o t h
enzymes. A similar analysis of residues of human fibri-
nogen that are citrullinated by rmPAD2 was performed,
which allowed the identification of 40 citrullinated resi-
dues, 23 in the a-chain, 13 in the b-chain and 4 in the
g-chain. Although the majority of these residues was
also deiminated by hPAD2 (17 in the a-chain, 7 in the
b-chain and 2 in the g-chain), some deiminated residues
were specifically detected in either the rmPAD2- or
hPAD2-treated material (Figure 2), which might be
related either to PAD specificity or undersampling by
the mass spectrometer.
Generation of citrullinated human fibrinogen peptides
To investigate which of the identified citrullinated resi-
dues in human fibrinogen are important for the recogni-
tion by autoantibodies in RA sera, in vitro citrullinated
fibrinogen was proteolytically digested and fractionated
by ion exchange chromatography. To this end, fibrino-
gen was citrullinated with rmPAD2, because the specific
activity of this enzyme is higher than that of hPAD2
and, as a consequence, the amount of PAD protein
needed was lower. Citrullinated fibrinogen was in this
case digested with either trypsin (T), chymotrypsin (C)
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peptides [24].
The individual digests were separated using SCX chro-
matography followed by mass spectrometry to identify
the citrullinated peptides present in the different frac-
tions. Adjacent fractions with largely overlapping peptide
compositions were pooled (Supplementary Figure S1 in
Additional file 1), giving a total of 29 fractions with dif-
ferent sets of citrullinated fibrinogen peptides that were
selected for iSPR analysis. The citrullinated peptide com-
position of these fractions is shown in Supplementary
Tables S1 (trypsin), S2 (Lys-N) and S3 (chymotrypsin) in
Additional file 1.
Recognition of citrullinated fibrinogen peptide
fractions by RA sera
The (pooled) SCX fractions were immobilized in discrete
spots on the surface of iSPR sensor discs and the reactivity
of 98 anti-CCP-positive and 4 anti-CCP-negative RA sera
with these fractions was monitored by iSPR measure-
ments, which we previously have shown to represent a sui-
table system to detect autoantibody reactivities against
multiple targets simultaneously [22,23]. Data generated
with iSPR can be depicted in a sensorgram, in which the
resonance angle shift is plotted against time. An example
of a sensorgram generated with this material is depicted in
Figure 4, which illustrates the reactivity of seven RA sera
with three fibrinogen peptide fractions (C8, L34 and T24)
and with a synthetic citrullinated peptide, which was used
as a positive control. The (resonance) angle shift resulting
from the association of serum antibodies to peptides on
the sensor disc surface was determined for each serum
and each spot (Figure 4a, inset). The use of 24 spots per
chip (Figure 4b) allowed the simultaneous analysis of mul-
tiple fractions, strongly reducing the total time required
for the experiment and increased the throughput of
Figure 2 In vitro citrullination of human fibrinogen. (a) Human fibrinogen (lane 1) was citrullinated in vitro with the recombinant hPAD2
(lane 2), hPAD4 (lane 3) and rmPAD2 (lane 4). The reaction products were analysed by SDS-PAGE and Coomassie Brilliant Blue staining (a) or by
western blotting followed by detection of citrullinated proteins by anti-modified citrulline antibodies after modification of proteins on the blot
(b, c). (c) Represents a longer exposure of the upper region of the blot shown in (b). The positions of the a-, b- and g-chains of fibrinogen are
indicated. Lane M contains a molecular weight marker and the molecular weights of the marker proteins are indicated on the left. In (b) lane C
contains deiminated soybean trypsin inhibitor as a positive control for the detection of citrullination.
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chips, together containing all fractions as well as positive
controls, were analyzed with all sera. The results clearly
s h o wt h a tt h ee f f i c i e n c yb yw h i c hs p e c i f i cf r a c t i o n sw e r e
recognized strongly differs between individual sera. For
example, serum 1 in Figure 4a is not reactive with any of
the citrullinated fibrinogen peptides, although it clearly
contains antibodies recognizing the positive control pep-
tide, whereas serum 4 is clearly reactive with at least two
of the citrullinated fibrinogen fractions.
We decided to classify the fibrinogen peptide fractions
based upon their reactivity with patient sera as defined
by angle shifts above a well-defined cutoff value and
upon the percentage of sera that showed reactivity (see
Methods). Nine of the 29 fractions were strongly recog-
nized by RA sera, while an additional 9 fractions
showed moderate levels of reactivity with RA sera
(Table 1).
The citrullinated peptides present in the strongly reac-
tive fractions are schematically aligned with the fibrino-
gen a-a n db-chains in Figure 5. This shows that the
most efficiently recognized citrullinated peptides corre-
spond to three regions of human fibrinogen. The citrul-
linated residues present in these regions are 216, 218,
573 and 591 in the a-chain and 60, 72 and 74 in the
b-chain (Supplementary Table S4 in Additional file 1).
Figure 3 Citrullination sites in human fibrinogen. Human fibrinogen was citrullinated in vitro by hPAD2, hPAD4 or rmPAD2 and citrullinated
residues were determined by proteolytic digestion followed by mass spectrometry. The positions of the citrullination sites are schematically
depicted in the three polypeptide chains of fibrinogen: hPAD2, filled circles; hPAD4, open circles; rmPAD2, filled triangles. The grey boxes at the
N-termini of the fibrinogen chains represent signal peptides (for all chains) and fibrinopeptides (for the a- and b-chains). Beneath each
fibrinogen chain (a, b or g), previously detected citrullination sites have been depicted; hPAD2, filled circles; hPAD4, open circles [15,16]. Amino
acid numbering is relative to the start of the signal peptides.
Figure 4 Analysis of autoantibody reactivity in patient sera by
iSPR. (a) Sensorgrams showing the reactivity of seven sera to
citrullinated peptides. The reactivity of seven RA sera with four
different spots on the array was determined by iSPR monitoring.
These spots contained either citrullinated fibrinogen fractions (C8,
L34 or T24) or a positive control peptide (pos). In the sensorgrams
the angle shifts in millidegrees (m°) are plotted as a function of
time. (b) Reconstructed image of an iSPR sensorchip showing the
resonance at 24 spots at a certain angle and a certain timepoint
during scanning of the array.
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In this paper we have applied a novel method to map
citrullinated epitopes of human fibrinogen that are
recognized by RA patient sera. This method is widely
applicable, not only for epitopes generated by post-
translational modifications, but also for epitopes consist-
ing of only standard amino acids. Three regions, two in
the a-a n do n ei nt h eb-chain, containing major epi-
topes for RA-autoantibodies were identified. The pre-
sence of citrullinated fibrinogen in the inflamed
synovium of rheumatoid arthritis patients [1] and the
detection of RA-associated autoantibodies against citrul-
linated fibrinogen imply that this protein is a genuine
autoantigen in RA [4] and previous studies have already
demonstrated that the citrullination of fibrinogen is
complex, with deiminated arginines on all three chains
and at various positions within these chains. Our com-
bined data identified 54 arginine residues that can be
deiminated by hPAD2, hPAD4 or rmPAD2 (Figure 3
and Supplementary Figure S2 in Additional file 1).
Thirty-two of these are associated with the a-chain, 17
with the b-chain and 5 with the g-chain. All previously
reported citrullination sites were found in our study
(Figure 3) [15,16]. In addition, 26 novel citrullination
sites were identified, 12 in the a-chain (positions 69, 84,
114, 135, 181, 186, 216, 218, 263, 353, 443 and 458), 10
in the b-chain (positions 47, 224, 246, 285, 376, 410,
421, 436, 445 and 485) and 4 in the g-chain (positions
40, 223, 282 and 417).
In total, 54 of the 81 arginines (66%) in human fibri-
nogen were found to be susceptible to citrullination
(Supplementary Figure S2 in Additional file 1). When
comparing individual PADs, both hPAD2 and rmPAD2
Table 1 Recognition of citrullinated fibrinogen peptide-containing fractions by RA sera
Strongly reactive fractions
a % reactive sera Moderately reactive fractions
b % reactive sera Non reactive fractions
c
T32 75 T31 54 C12
T27 57 L34 47 C14
C8 51 C10 44 C22
T28 51 L33 43 C25
T26 50 C27 36 C31
L37 46 L27 36 C34
L28 39 C29 33 L24
T29 39 C28 30 L26
T24 36 C30 25 L29
L30
L31
a Fractions that are recognized by at least 25% of the RA sera with reactivities exceeding a cut-off value of the mean plus 8 times the standard deviation of anti-
CCP-negative sera. T, C and L refer to the proteases used to fragment citrullinated fibrinogen; numbers correspond to fraction numbers of the fractionation by
cation exchange chromatography.
b Fractions that are recognized by at least 25% of the RA sera with reactivities exceeding a cut-off value of the mean plus two times the standard deviationo f
anti-CCP-negative sera.
cThe remaining fractions that were analysed.
RA, rheumatoid arthritis.
Figure 5 Mapping of major citrullinated fibrinogen epitopes
recognized by RA sera. The citrullinated peptides present in the
most strongly reactive fractions are schematically aligned with the
a- and b-chains of fibrinogen. Asterisks indicate the citrullinated
residues in the peptides. Citrullinated peptides (obtained by in vitro
citrullination with rmPAD2) that are present in the most reactive
fractions of at least two of the three proteolytic digests are
highlighted in dark grey, whereas the other peptides in these
fractions are indicated with the light grey boxes.
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citrullinated by hPAD4. The higher number of residues
citrullinated by PAD2 compared to PAD4 is in agree-
ment with observations that the amino acid context of
the peptidylarginine is more important for PAD4 than
for PAD2 (manuscript in preparation; [25]).
The digestion of citrullinated fibrinogen with three dis-
tinct proteases to analyze autoantibody reactivities with
the fractionated peptides implied that a large part of the
(citrullinated) protein was covered by peptides suitable
for both LC-MS/MS analysis and immobilization. An
important advantage of iSPR is that it can be used to
monitor the reactivity of patient sera with multiple
antigenic molecules simultaneously, which is less time-
consuming and more accurate than other current meth-
o d st os c r e e ns e r a ,s u c ha sE L I S A .T h eiSPR results
obtained with the fractionated proteolytic digests of fibri-
nogen revealed that RA sera are reactive with specific
regions of citrullinated fibrinogen. These regions are pre-
sent in the fibrinogen sequence around the citrullinated
residues at position 216, 218, 573 and 591 of the a-chain
and at positions 60, 72 and 74 of the b-chain. Previously,
several studies have reported the reactivity of RA sera
with citrullinated epitopes of fibrinogen. The data related
to the epitopes identified in our study are summarized in
Table 2[4,7,9,15,16]. Although some overlap between
these data is observed, also clear differences are present,
which may at least in part be due to the differences in the
Table 2 Citrullinated fibrinogen epitopes detected also in previous studies
Reference Peptide used
a Citrullination
sites
Fibrinogen
chain
Percentage of reactive sera
(%)
Sebbag et al. [4]. ___________RDRQHLPLIKMKPVP 216, 218 a 0
_________LPSRDRQHLPLIKMK 216, 218 a 0
Perez et al. [9]. ____IAKDLLPSRDRQHLPLIK 216 a 18
____IAKDLLPSRDRQHLPLIK 218 a 0
____IAKDLLPSRDRQHLPLIK 216, 218 a 0
Sebbag et al. [4]. _____________SSHHPGIAEFPRGK 573 a 25
Kubota et al. [15]. ___SGIFTNTKESSSHHPGIAEFPRGKSSSY 573 a n.d.
Nakayama-Hamada
et al. [16].
b) 573 a n.d.
Sebbag et al. [4]. _____________RGDSTFESKSYKMAD 591 a 0
__________SYNRGDSTFESKSYK 591 a 20
Kubota et al. [15]. ____QFTSSTSYNRGDSTFESKS 591 a n.d.
Nakayama-Hamada
et al. [16].
b) 591 a n.d.
Perez et al. [9]. ARGHRPLDKKREEAPSLRPA 44, 47, 53, 60 b 3
ARGHRPLDKKREEAPSLRPA 47, 53, 60 b 9
ARGHRPLDKKREEAPSLRPA 44, 53, 60 b 6
Sebbag et al. [4]. _______DKKREEAPSLRPAPP 53,60 b 0
Perez et al. [9]. ARGHRPLDKKREEAPSLRPA 53,60 b 12
ARGHRPLDKKREEAPSLRPA 60 b 12
ARGHRPLDKKREEAPSLRPA 44, 60 b 0
ARGHRPLDKKREEAPSLRPA 47, 60 b 36
ARGHRPLDKKREEAPSLRPA 44, 47, 60 b 12
______________RARPAKAAATQKKVERKA 72 b 0
______________RARPAKAAATQKKVERKA 74 b 0
Sebbag et al. [4]. __RPAPPPISGGGYRAR 60, 72, 74 b 28
Hill et al. [7]. ___________GGYRARPAKAAAT 72, 74 b 0
Perez et al. [9]. _____________RARPAKAAATQKKVERKA 72, 74 b 0
Nakayama-Hamada et al.
[16].
b) 53, 60, 72, 74 b n.d.
Perez et al. [9]. _____________RARPAKAAATQKKVERKA 72, 87 b 0
_____________RARPAKAAATQKKVERKA 74, 87 b 0
_____________RARPAKAAATQKKVERKA 72, 74, 87 b 0
a) Arginines that can be citrullinated by either hPAD2, hPAD4 or rmPAD2 are highlighted in bold.
b) Nakayama-Hamada and colleagues only showed the identified citrullination sites and not which peptides containing the sites were found.
n.d.: not determined.
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Page 8 of 10peptides that were used and the procedures that were
applied to immobilize these peptides. Using synthetic
peptides the N-terminal region of the a-chain of human
fibrinogen (with citrullinated residues at positions 38 and
42) was observed to be frequently targeted by RA sera
[4]. Because these residues were not detectably citrulli-
nated by rmPAD2, our data do not allow conclusions
concerning the recognition of this region of fibrinogen by
RA sera. In contrast, citrullination of the arginine resi-
dues at positions 216 and 218 of the a-chain have not
been reported in previous studies, in which fibrinogen
was citrullinated by hPAD2 or hPAD4 (Figure 3) [15,16],
which is most likely due to the inclusion of rmPAD2 in
the present study. The poor recognition of synthetic pep-
tides comprising this region of fibrinogen by RA sera in
previous studies [4,9] might be explained by differences
in the presentation of the epitope(s) by (partially) differ-
ent peptides. Currently we are using synthetic citrulli-
nated peptides derived from the data presented in Figure
5 to verify the presence of major epitopes targeted by RA
autoantibodies at these positions in fibrinogen and to
investigate their diagnostic and prognostic value in more
detail.
The citrullinated epitopes of fibrinogen reactive with RA
sera are particularly relevant for diagnostic applications,
since citrullinated human fibrinogen displays a sensitivity
and specificity very similar to the widely used anti-CCP
test for ACPA detection [10]. The use of individual citrulli-
nated peptides in a multiplex assay, however, enables a bet-
ter quality control of diagnostic test performance and the
results of this study indeed can be used to rationally design
the peptides for such multiplex systems. The need for mul-
tiplex ACPA analysis systems has recently increased by the
observations that the so-called fine-specificity of these anti-
bodies has a predictive value for the way the disease will
progress [26,27]. It would be particularly interesting to ana-
lyze the ACPA response to the citrullinated fibrinogen epi-
topes in various stages of (early) RA and to compare the
reactivity profiles with clinical features, which may provide
opportunities for more personalized treatment.
Knowledge on the citrullinated autoepitopes targeted
by the antibodies in the inflamed synovia of RA patients
is also important for a better understanding of the
pathophysiology, because the resulting immune com-
plexes may directly contribute to the progression and
chronicity of the disease [28].
Conclusions
A new method was developed for the comprehensive
analysis of epitopes that are formed by post-translational
modifications using the (enzymatically modified) protein
of interest as starting material. This method, in which
chromatographic fractionation of proteolytic digests is
combined with mass spectrometry and surface plasmon
resonance imaging on microarrays, allows the simulta-
neous mapping of modified residues and epitopes. Using
this method, fifty four citrullination sites and three
citrullinated epitope regions frequently recognized by
A C P Ai nt h es e r ao fR Ap a t i e n t sw e r ei d e n t i f i e di n
human fibrinogen, one of the main autoantigenic pro-
teins in this disease.
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